Combination of alpha-1 antitrypsin and doxycycline suppresses collagen-induced arthritis
Christian Grimstein1, Young-Kook Choi, Minoru Satoh
1Department of Pharmaceutics, University of Florida, Gainesville, FL 32610, USA.
Background:
Rheumatoid arthritis (RA) is a complex disease characterized by autoimmune inflammation and joint destruction. Despite recent advances in RA treatment, current therapies require further improvement to overcome adverse events and ineffectiveness in some cases. By targeting different pathways/molecules using drug combinations, a better treatment can be obtained, whereas adverse events are reduced. In order to develop a new treatment option, the present study employs a gene therapy-based combination therapy using doxycycline and human alpha-1 antitrypsin (hAAT).
Methods:
DBA/1 mice were immunized with type II collagen to induce arthritis. Four weeks before immunization, they received a doxycycline containing diet and a single injection of adeno-associated virus vector expressing hAAT under the control of a tetracycline-dependent promoter. Control groups received doxycycline alone or saline. Macroscopic arthritis development as well as histopathological changes in the joint were evaluated. In addition, the effects of hAAT and doxycycline on lipopolysaccharide (LPS)- or tumor necrosis factor-alpha-induced interleukin (IL)-6 production from mouse fibroblast cells were also determined.
Results:
Combination therapy significantly reduced arthritis development and progression compared to the control group in respect to macroscopic as well as histopathological changes. Doxycycline and hAAT in combination also inhibited IL-6 expression from LPS-stimulated NIH/3T3 mouse fibroblast cells, indicating a contributing mechanism of arthritis inhibition.
Conclusions:
The results obtained in the present study indicate that a combination therapy using AAT and doxycycline holds promising potential as a new therapy for RA.
Insights
This study shows that combining doxycycline and human alpha-1 antitrypsin (hAAT) gene therapy effectively reduces rheumatoid arthritis (RA) development and inflammation. This combination therapy offers a promising new treatment strategy for RA patients.
Area of Science:
- Immunology
- Gene Therapy
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is an autoimmune disease causing joint inflammation and destruction.
- Current RA treatments have limitations including adverse events and variable effectiveness.
- Combination therapies targeting multiple pathways may improve RA treatment outcomes.
Purpose of the Study:
- To investigate the potential of a novel gene therapy-based combination treatment for rheumatoid arthritis.
- To evaluate the efficacy of combining doxycycline and human alpha-1 antitrypsin (hAAT) in an arthritis model.
Main Methods:
- Type II collagen-induced arthritis was established in DBA/1 mice.
- Mice received doxycycline and an adeno-associated virus vector expressing hAAT.
- Arthritis progression, joint pathology, and IL-6 production were assessed.
Main Results:
- Combination therapy significantly reduced macroscopic and histopathological signs of arthritis.
- Doxycycline and hAAT together inhibited IL-6 production in stimulated fibroblast cells.
- These findings suggest a mechanism for the observed arthritis inhibition.
Conclusions:
- Combination therapy with hAAT and doxycycline demonstrates significant potential for treating rheumatoid arthritis.
- This approach may offer an improved therapeutic option for RA management.
Related Concept Videos
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
01:11Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:26COPD: Management Using Bronchodilators and Corticosteroids